Ovaleap® (follitropin alfa) is indicated:
In adult women:
In adult men:
Each mL of the solution contains 600IU (equivalent to 44mcg) follitropin alfa. Follitropin alfa (recombinant human follicle-stimulating hormone [r-hFSH]) is produced in Chinese Hamster Ovary Cells (CHO DHFR) via recombinant DNA technology.1
Each cartridge contains either 300IU, 450IU or 900IU of Ovaleap® for injection.1
Ovaleap® is a clear, colourless solution intended for subcutaneous administration with a pH of 6.8-7.2.1
As the Ovaleap® multi-dose cartridge is intended for several injections, clear instructions should be provided to the patients to avoid misuse of the multi-dose presentation.
The Ovaleap® cartridge is designed for use in conjunction with the Ovaleap® Pen® only, available separately.1
Marketing Authorisation Number(s)
1 Ovaleap® (follitropin alfa) Summary of Product Characteristics.
To access this section of the Teva UK Limited website you need to be a member of the healthcare profession
because the materials included in this area of our website are specifically prepared for that audience
To understand why that is - please visit: Working in a regulated environment
Please click on the appropriate button below to confirm that you are healthcare professional.
If you are not a healthcare professional, you will be taken to an area of the website that is appropriate for you.